Stock market today: S&P 500 hits fresh record close on stronger economic growth
FMR LLC, a ten percent owner of Beam Therapeutics Inc . (NASDAQ:BEAM), sold 48,374 shares of common stock on July 30, 2025, at a price of $20.50, according to a Form 4 filing with the Securities and Exchange Commission. The total value of the transaction amounted to $991,667. The sale price represents a premium to the current trading price of $19.30, with the stock down nearly 35% over the past year. According to InvestingPro analysis, BEAM appears slightly undervalued based on its Fair Value assessment.
Following the transaction, FMR LLC continues to own 2,073,665 shares held by persons and entities whose shares are subject to reporting by the undersigned, 1,139,443 shares held by F-Prime Capital Partners (WA:CPAP) Healthcare Fund V LP and 473 shares held by FMR Capital, Inc. With a market capitalization of $1.88 billion and an overall Financial Health score rated as "FAIR" by InvestingPro, investors can access comprehensive analysis including 12+ key financial metrics and detailed Pro Research Reports available exclusively for subscribers.
In other recent news, Beam Therapeutics Inc. has reported positive data from its BEACON Phase 1/2 clinical trial of BEAM-101, a base-editing therapy for sickle cell disease (SCD). The trial data from 17 patients showed significant improvements, with hemoglobin F levels exceeding 60% and sickle hemoglobin levels dropping below 40%. Additionally, Beam Therapeutics’ BEAM-101 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA), which aims to facilitate the development of treatments for rare diseases like SCD. In another development, the company received FDA orphan drug status for BEAM-302, its investigational treatment for alpha-1 antitrypsin deficiency (AATD). This designation offers benefits such as tax credits and potential market exclusivity upon approval. H.C. Wainwright has reiterated its Buy rating on Beam Therapeutics, with an $80 target price, highlighting the company’s innovative technology and promising trial results. These recent developments indicate ongoing advancements in Beam’s therapeutic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.